Advertisement
Screener

NewAmsterdam Pharma Company N.V. (NAMS) Share Premium

2.8 / 5 stars · 68/120 Roast Me

NewAmsterdam Pharma Company N.V. Share Premium

NewAmsterdam Pharma Company N.V. (NAMS) had Share Premium of EUR 589.40 million as of 2022-12-31, per its 20-F/A filed 2024-10-28.

Financial Statements › Notes

ifrs-full:SharePremium · last filed 2024-10-28

  • 2022-12-31: Share Premium 589.40M EUR.
  • 2022-11-22: Share Premium 163.39M EUR.
  • 2021-12-31: Share Premium 83.76M EUR.
  • 2020-12-31: Share Premium 2.45M EUR.
Period endShare Premium
2022-12-31589.40M EUR
20-F/A · filed 2024-10-28
2022-11-22163.39M EUR
20-F/A · filed 2024-10-28
2021-12-3183.76M EUR
20-F/A · filed 2024-10-28
2020-12-312.45M EUR
20-F/A · filed 2024-10-28
2019-12-312.48M EUR
20-F/A · filed 2024-10-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67